Anebulo Pharmaceuticals (ANEB) Competitors $1.40 +0.00 (+0.36%) As of 03/28/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANEB vs. CDTX, ACB, TSVT, CRDF, OLMA, DRUG, LFCR, MNPR, ENGN, and FHTXShould you be buying Anebulo Pharmaceuticals stock or one of its competitors? The main competitors of Anebulo Pharmaceuticals include Cidara Therapeutics (CDTX), Aurora Cannabis (ACB), 2seventy bio (TSVT), Cardiff Oncology (CRDF), Olema Pharmaceuticals (OLMA), Bright Minds Biosciences (DRUG), Lifecore Biomedical (LFCR), Monopar Therapeutics (MNPR), enGene (ENGN), and Foghorn Therapeutics (FHTX). These companies are all part of the "pharmaceutical products" industry. Anebulo Pharmaceuticals vs. Cidara Therapeutics Aurora Cannabis 2seventy bio Cardiff Oncology Olema Pharmaceuticals Bright Minds Biosciences Lifecore Biomedical Monopar Therapeutics enGene Foghorn Therapeutics Cidara Therapeutics (NASDAQ:CDTX) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Does the media prefer CDTX or ANEB? In the previous week, Cidara Therapeutics had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 3 mentions for Cidara Therapeutics and 2 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 1.44 beat Cidara Therapeutics' score of 0.30 indicating that Anebulo Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Cidara Therapeutics Neutral Anebulo Pharmaceuticals Positive Does the MarketBeat Community believe in CDTX or ANEB? Cidara Therapeutics received 446 more outperform votes than Anebulo Pharmaceuticals when rated by MarketBeat users. However, 90.00% of users gave Anebulo Pharmaceuticals an outperform vote while only 70.43% of users gave Cidara Therapeutics an outperform vote. CompanyUnderperformOutperformCidara TherapeuticsOutperform Votes45570.43% Underperform Votes19129.57% Anebulo PharmaceuticalsOutperform Votes990.00% Underperform Votes110.00% Which has higher valuation and earnings, CDTX or ANEB? Anebulo Pharmaceuticals has lower revenue, but higher earnings than Cidara Therapeutics. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$1.28M192.34-$22.93M-$30.09-0.74Anebulo PharmaceuticalsN/AN/A-$8.20M-$0.28-4.86 Which has more risk & volatility, CDTX or ANEB? Cidara Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Anebulo Pharmaceuticals has a beta of -1.09, suggesting that its stock price is 209% less volatile than the S&P 500. Do insiders & institutionals believe in CDTX or ANEB? 35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 7.6% of Cidara Therapeutics shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is CDTX or ANEB more profitable? Anebulo Pharmaceuticals has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Cidara Therapeutics' return on equity of -69.64% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Cidara Therapeutics-289.05% -69.64% -33.73% Anebulo Pharmaceuticals N/A -119.54%-108.08% Do analysts recommend CDTX or ANEB? Cidara Therapeutics currently has a consensus price target of $39.14, indicating a potential upside of 74.82%. Anebulo Pharmaceuticals has a consensus price target of $8.00, indicating a potential upside of 488.24%. Given Anebulo Pharmaceuticals' higher probable upside, analysts clearly believe Anebulo Pharmaceuticals is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCidara Therapeutics beats Anebulo Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Remove Ads Get Anebulo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANEB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANEB vs. The Competition Export to ExcelMetricAnebulo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.88M$6.90B$5.63B$7.84BDividend YieldN/A2.75%5.33%4.01%P/E Ratio-4.867.2623.5318.72Price / SalesN/A218.61388.1990.75Price / CashN/A65.6738.1734.64Price / Book9.076.386.894.23Net Income-$8.20M$142.34M$3.20B$247.47M7 Day Performance-15.53%-5.15%-3.06%-2.29%1 Month Performance17.24%-7.55%1.51%-5.81%1 Year Performance-52.61%-11.06%9.35%-0.94% Anebulo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANEBAnebulo Pharmaceuticals2.9431 of 5 stars$1.36-2.9%$8.00+488.2%-52.6%$55.88MN/A-4.864Short Interest ↓Positive NewsCDTXCidara Therapeutics4.3567 of 5 stars$23.63+5.2%$39.14+65.6%+21.7%$258.82M$1.28M-0.9390Short Interest ↑ACBAurora Cannabis0.3055 of 5 stars$4.57+2.5%N/A+0.9%$256.14M$320.81M91.421,340TSVT2seventy bio2.9369 of 5 stars$4.96+0.2%$6.67+34.4%-7.5%$255.88M$45.62M-2.67440Earnings ReportShort Interest ↓CRDFCardiff Oncology1.7824 of 5 stars$3.79+1.1%$11.67+207.8%-38.4%$249.47M$683,000.00-4.0320Positive NewsOLMAOlema Pharmaceuticals2.7017 of 5 stars$4.32+2.1%$27.50+536.6%-63.7%$247.53MN/A-1.9770Analyst ForecastHigh Trading VolumeDRUGBright Minds Biosciences2.7605 of 5 stars$34.80-1.0%$84.33+142.3%+2,941.9%$245.13MN/A-204.69N/APositive NewsLFCRLifecore Biomedical1.3565 of 5 stars$6.60+0.8%$8.00+21.2%+29.0%$244.37M$130.86M-11.79690News CoverageMNPRMonopar Therapeutics1.1703 of 5 stars$37.60-6.0%$44.00+17.0%+1,084.4%$244.10MN/A-19.0910Gap UpENGNenGene3.1823 of 5 stars$4.63-6.7%$25.22+444.8%-74.6%$236.02MN/A-7.9831FHTXFoghorn Therapeutics2.634 of 5 stars$4.22+4.2%$13.17+212.0%-47.5%$234.68M$22.60M-2.20120Positive NewsGap Up Remove Ads Related Companies and Tools Related Companies Cidara Therapeutics Alternatives Aurora Cannabis Alternatives 2seventy bio Alternatives Cardiff Oncology Alternatives Olema Pharmaceuticals Alternatives Bright Minds Biosciences Alternatives Lifecore Biomedical Alternatives Monopar Therapeutics Alternatives enGene Alternatives Foghorn Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANEB) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersNew Pick (93% history of rising by May 8)We just posted a new recommendation. Keep in mind: You could have boosted the Netflix trade we issued to the p...InvestorPlace | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANEB Stock Free ANEB Stock Alerts